Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Amminger

Showing results (21-30 of 191) with videos related to

Pageof 20
Sort By:
The Journal of Clinical Psychiatry|December 17, 2013
Dr McGorry and colleagues replyPatrick D McGorry, Alison R Yung, Barnaby Nelson, et al.
Drug Testing and Analysis|October 23, 2020
A validated method for the simultaneous quantification of cannabidiol, Δ<sup>9</sup> -tetrahydrocannabinol, and their metabolites in human plasma and application to plasma samples from an oral cannabidiol open-label trialRichard C Kevin, Rebecca Vogel, Peter Doohan, et al.
Psychiatry Research|May 17, 2015
Erythrocyte polyunsaturated fatty acid levels in young people at ultra-high risk for psychotic disorder and healthy adolescent controlsSimon M Rice, Miriam R Schäfer, Claudia Klier, et al.
Frontiers in Psychiatry|June 16, 2020
Commentary: Preventive Treatments for Psychosis: Umbrella Review (Just the Evidence)Barnaby Nelson, G Paul Amminger, Andrew Thompson, et al.
Biological Psychiatry|August 22, 2006
Omega-3 fatty acids supplementation in children with autism: a double-blind randomized, placebo-controlled pilot studyG Paul Amminger, Gregor E Berger, Miriam R Schäfer, et al.
Current Opinion in Psychiatry|June 7, 2007
Age of onset of mental disorders: a review of recent literatureRonald C Kessler, G Paul Amminger, Sergio Aguilar-Gaxiola, et al.
Australasian Psychiatry : Bulletin of Royal Australian and New Zealand College of Psychiatrists|April 5, 2017
Novel biotherapies are needed in youth mental healthG Paul Amminger, Maximus Berger, Simon M Rice, et al.
Schizophrenia Research|September 19, 2012
The Community Assessment of Psychic Experience (CAPE) questionnaire as a screening-instrument in the detection of individuals at ultra-high risk for psychosisNilufar Mossaheb, Jana Becker, Miriam R Schaefer, et al.
Schizophrenia Research|September 11, 2012
Social cognition in clinical "at risk" for psychosis and first episode psychosis populationsAndrew Thompson, Alicia Papas, Cali Bartholomeusz, et al.
Early Intervention in Psychiatry|October 28, 2014
Indicated prevention with long-chain polyunsaturated omega-3 fatty acids in patients with 22q11DS genetically at high risk for psychosis. Protocol of a randomized, double-blind, placebo-controlled treatment trialMarco Armando, Franco De Crescenzo, Stefano Vicari, et al.
Pageof 20

Showing results (21-30 of 191) with videos related to

Sort By:
Pageof 20
The Journal of Clinical Psychiatry|December 17, 2013
Dr McGorry and colleagues replyPatrick D McGorry, Alison R Yung, Barnaby Nelson, et al.
Drug Testing and Analysis|October 23, 2020
A validated method for the simultaneous quantification of cannabidiol, Δ<sup>9</sup> -tetrahydrocannabinol, and their metabolites in human plasma and application to plasma samples from an oral cannabidiol open-label trialRichard C Kevin, Rebecca Vogel, Peter Doohan, et al.
Psychiatry Research|May 17, 2015
Erythrocyte polyunsaturated fatty acid levels in young people at ultra-high risk for psychotic disorder and healthy adolescent controlsSimon M Rice, Miriam R Schäfer, Claudia Klier, et al.
Frontiers in Psychiatry|June 16, 2020
Commentary: Preventive Treatments for Psychosis: Umbrella Review (Just the Evidence)Barnaby Nelson, G Paul Amminger, Andrew Thompson, et al.
Biological Psychiatry|August 22, 2006
Omega-3 fatty acids supplementation in children with autism: a double-blind randomized, placebo-controlled pilot studyG Paul Amminger, Gregor E Berger, Miriam R Schäfer, et al.
Current Opinion in Psychiatry|June 7, 2007
Age of onset of mental disorders: a review of recent literatureRonald C Kessler, G Paul Amminger, Sergio Aguilar-Gaxiola, et al.
Australasian Psychiatry : Bulletin of Royal Australian and New Zealand College of Psychiatrists|April 5, 2017
Novel biotherapies are needed in youth mental healthG Paul Amminger, Maximus Berger, Simon M Rice, et al.
Schizophrenia Research|September 19, 2012
The Community Assessment of Psychic Experience (CAPE) questionnaire as a screening-instrument in the detection of individuals at ultra-high risk for psychosisNilufar Mossaheb, Jana Becker, Miriam R Schaefer, et al.
Schizophrenia Research|September 11, 2012
Social cognition in clinical "at risk" for psychosis and first episode psychosis populationsAndrew Thompson, Alicia Papas, Cali Bartholomeusz, et al.
Early Intervention in Psychiatry|October 28, 2014
Indicated prevention with long-chain polyunsaturated omega-3 fatty acids in patients with 22q11DS genetically at high risk for psychosis. Protocol of a randomized, double-blind, placebo-controlled treatment trialMarco Armando, Franco De Crescenzo, Stefano Vicari, et al.
Pageof 20